ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2809

Increased Frequencies of IL-23R Positive T Cells and IL-22 and IL-17 Producing MAIT Cells in the Peripheral Blood of Patients with Ankylosing Spondylitis: Preliminary Results.   

Eric Toussirot1, Caroline Laheurte2, Béatrice Gaugler3 and Philippe Saas4, 1Service de Rhumatologie, CHU J Minjoz, Besancon, France, 2Etablissement Français du Sang/ Université de Franche Comté / CBT506 / CHRU, INSERM UMR1098 / Plateforme Biomonitoring, Besançon, France, 3EFS Bourgogne Franche Comté, INSERM UMR1098 / Etablissement Français du Sang / Université de Franche Comté, Besançon, France, 4Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ankylosing spondylitis (AS) and mucosal T cells, IL-23

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Poster I

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Ankylosing spondylitis (AS) is the prototypic and most common form of spondyloarthritis (SpA). It was recently suggested that IL-23 could play a pivotal role in the pathophysiology of SpA. Indeed, there is a strong genetic association of SpA with polymorphisms of the IL-23 receptor (IL-23R) gene. In experimental models, IL-23 is produced during the misfolding phenomenon of HLA-B27 heavy chain in the endoplasmic reticulum. Furthermore, in animal models, IL-23 overexpression induced a SpA-like disease via resident IL-23+ T cells infiltrating entheseal structures and producing IL-17 and IL-22. In addition, there is an increased number of circulating cells producing IL-17 in patients with AS. Recent data also suggested that IL-17A is a potential target in the treatment of patients with AS.

Objectives: Cells that expressed IL-23R, as well as those producing IL-17 and/or IL-22 have been poorly characterized in AS and/or SpA. Thus, we aimed to better delineate the peripheral blood T cells that expressed IL-23R and the IL-17 and IL-22 producing cell subsets, notably conventional T cells as well as mucosal-associated invariant T cells (MAIT) in patients with AS.

Methods:   36 patients with AS (modified NY criteria; 27 M; age: 44.7 ± 2.6, disease duration: 12.7 ± 1.6; all under NSAIDs or traditional DMARDs) and 31 healthy controls (HC) (8 M; age: 46 ± 2.3) were evaluated. For each subject, peripheral blood T cell subsets were assessed using multi-color flow cytometry. Intracellular cytokine IL-17A, IL-22 and IFN-γ were evaluated after phorbol myristate acetate and ionomycine activation and permeabilization and analysed by flow cytometry. MAIT cells were identified by using TCRVα7.2 specific monoclonal antibodies. IL-22 serum levels were determined by ELISA using commercially available kit.

Results:   the number and percentage of CD3+ T cells, CD3+CD4+ and CD3+CD8+ T cells were comparable between patients and HC. Circulating IL-22 levels did not differ between patients and HC (22.6 ± 8.4 vs 15.1 ± 4.4 pg/ml, p = 0.7). IFN-γ producing CD4+ and CD8+ T cells were decreased in AS compared to HC (4.6 ± 1.7 vs 11.4 ± 2.5 % and 23.3 ± 1.9 vs 34.3 ± 2.3 %, respectively, p = 0.005 and p = 0.002). CD8+ T cells expressing IL-23R were significantly increased in AS: 72.8 ± 1.5 vs 65.2 ± 2 % (p = 0.009). The percentage of MAIT T cells did not differ between patients and HC but we found an increased percentage of MAIT cells that produced IL-17 and IL-22: MAIT IFN-γ– IL-17+: 0.43 ± 0.1 vs 0.12 ± 0.008 %, p = 0.006; MAIT IFN-γ– IL-22+: 0.83 ± 0.1 vs 0.3 ± 0.1 %, p = 0.004. No correlation was found between the percentage of IL-23R+ CD8+ T cells and measurements of disease activity, as well as between IL-17+ or IL-22+ MAIT cells and disease activity.

Conclusion:  These preliminary results suggest that the peripheral blood of patients with AS is enriched in IL-23R+ CD8+ T cells, as well as IL-17 and IL-22 producing MAIT cells. Since MAIT cells are involved in antibacterial immunity and bacterial agents are potentially involved in SpA, our preliminary data suggest that this T cell subset could potentially play a role in AS via IL-17 and IL-22 production. This remains to be clarified by future and complementary studies.


Disclosure: E. Toussirot, None; C. Laheurte, None; B. Gaugler, None; P. Saas, None.

To cite this abstract in AMA style:

Toussirot E, Laheurte C, Gaugler B, Saas P. Increased Frequencies of IL-23R Positive T Cells and IL-22 and IL-17 Producing MAIT Cells in the Peripheral Blood of Patients with Ankylosing Spondylitis: Preliminary Results.    [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/increased-frequencies-of-il-23r-positive-t-cells-and-il-22-and-il-17-producing-mait-cells-in-the-peripheral-blood-of-patients-with-ankylosing-spondylitis-preliminary-results/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-frequencies-of-il-23r-positive-t-cells-and-il-22-and-il-17-producing-mait-cells-in-the-peripheral-blood-of-patients-with-ankylosing-spondylitis-preliminary-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology